Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (16750)	3/7/1998 8:51:00 PM
From: Hippieslayer	Respond to of 32384

Was just at the local Crown book store and happened to see that Jim McMamant (of MTSL-Medical TEch Stock Letter) recommended Ligand in the most recent issue of "WORTH". I got scared because at first glance I thought it was Murphy who was giving the recommendation.

To: Henry Niman who wrote (16750)	3/9/1998 1:31:00 PM
From: tuck	Read Replies (1) \| Respond to of 32384

Henry, I appreciate the clarification regarding SERM's; clearly I had a slight aural misunderstanding. On the clued -- clueless spectrum, I am towards the clueless end, I admit. But I have my sources, as those with long memories on the thread may recall. I do not know on what basis the "strong speculation" that the Lilly drug is DAB IL-2 is founded, but I will stick to my guns regarding the SERM, particularly after reading your comment on it regarding synergistic effects with rexinoids. After Ligand does go public with its choice, I will try to remember to tell you the story, if only to shore my credibility a tad. I agree that Lilly would not give Ligand a blockbuster SERM. But humor me for a minute, and assume it is a SERM. What market do you think it might address? I revisited your Ligand Links page, and I must say, it's very impressive. Great work! I will be there more often in an effort to become more clued. Regards, Tuck